REGN — Regeneron PharmaceuticalsFREE
Price
$607.93
previous close
Median target
$857.5
across current calls
Implied return
+41.0%
median target vs. price
Coverage
30 analysts · 36 calls
current predictions
Consensus
26/9/1+25 net
Buy / Hold / Sell
Current analyst calls on REGN
Sorted by implied return. Each row is one analyst's live rating and price target.
| Analyst | Score | Rank | Succ% | Ret% | Firm | Call | Target | Impl. return | Updated |
|---|---|---|---|---|---|---|---|---|---|
| Robyn Karnauskas | – | – | – | Truist Securities | Buy | $1,200 | +97.4% | Sep 23, 2024 | |
| Jasper Hellweg | – | – | – | Argus Research | Buy | $1,170 | +92.5% | Jun 25, 2024 | |
| Alexandria Hammond | – | – | – | Wolfe Research | Buy | $1,150 | +89.2% | Nov 15, 2024 | |
| Yatin Suneja | – | – | – | Guggenheim | Buy | $995 | +63.7% | May 1, 2026 | |
| Salveen Richter | – | – | – | Goldman Sachs | Buy | $968 | +59.2% | May 18, 2026 | |
| Nicholas Lorusso | – | – | – | TD Cowen | Buy | $960 | +57.9% | May 6, 2026 | |
| Dane Leone | – | – | – | Raymond James | Buy | $950 | +56.3% | Nov 2, 2023 | |
| William Pickering | – | – | – | Bernstein | Buy | $921 | +51.5% | Apr 8, 2026 | |
| Eliana Merle | – | – | – | Barclays | Buy | $917 | +50.8% | Apr 30, 2026 | |
| Eliana Merle | – | – | – | Barclays | Buy | $917 | +50.8% | May 18, 2026 | |
| Hartaj Singh | – | – | – | Oppenheimer | Buy | $900 | +48.0% | Apr 29, 2025 | |
| Akash Tewari | – | – | – | Jefferies | Buy | $890 | +46.4% | Mar 11, 2026 | |
| Cory Kasimov | – | – | – | Evercore ISI Group | Buy | $875 | +43.9% | Jan 22, 2026 | |
| John Newman | – | – | – | Canaccord Genuity | Buy | $875 | +43.9% | May 19, 2026 | |
| Christopher Raymond | – | – | – | Raymond James | Buy | $870 | +43.1% | Jan 30, 2026 | |
| Matthew Biegler | – | – | – | Oppenheimer | Buy | $865 | +42.3% | Feb 2, 2026 | |
| Michael King | – | – | – | Rodman & Renshaw | Buy | $862 | +41.8% | May 1, 2023 | |
| Alexandria Hammond | – | – | – | Wolfe Research | Buy | $860 | +41.5% | May 18, 2026 | |
| Biren Amin | – | – | – | Piper Sandler | Buy | $855 | +40.6% | May 18, 2026 | |
| Chris Schott | – | – | – | J.P. Morgan | Buy | $850 | +39.8% | May 18, 2026 | |
| Akash Tewari | – | – | – | Jefferies | Buy | $831 | +36.7% | Aug 27, 2025 | |
| Cory Kasimov | – | – | – | Evercore ISI Group | Buy | $825 | +35.7% | May 18, 2026 | |
| Carter Gould | – | – | – | Cantor Fitzgerald | Buy | $800 | +31.6% | Apr 23, 2026 | |
| Carter Gould | – | – | – | Cantor Fitzgerald | Buy | $800 | +31.6% | Apr 29, 2026 | |
| Gregory Renza | – | – | – | Truist Securities | Buy | $778 | +28.0% | May 18, 2026 | |
| Louise Chen | – | – | – | Scotiabank | Hold | $770 | +26.7% | May 19, 2026 | |
| Louise Chen | – | – | – | Scotiabank | Hold | $770 | +26.7% | Nov 24, 2025 | |
| Evan Seigerman | – | – | – | BMO Capital | Buy | $730 | +20.1% | May 18, 2026 | |
| Brian Abrahams | – | – | – | RBC Capital | Hold | $707 | +16.3% | May 17, 2026 | |
| Geoff Meacham | – | – | – | Citigroup | Hold | $700 | +15.1% | May 18, 2026 | |
| Mohit Bansal | – | – | – | Wells Fargo | Hold | $700 | +15.1% | May 18, 2026 | |
| Trung Huynh | – | – | – | RBC Capital | Hold | $660 | +8.6% | Nov 7, 2025 | |
| Andrew Berens | – | – | – | Leerink Partners | Hold | $641 | +5.4% | May 18, 2026 | |
| David Risinger | – | – | – | Leerink Partners | Hold | $641 | +5.4% | May 18, 2026 | |
| Tim Anderson | – | – | – | B of A Securities | Sell | $627 | +3.1% | Oct 29, 2025 | |
| Brian Skorney | – | – | – | Baird | Hold | $587 | -3.4% | Apr 30, 2025 |
Analyst track records are Premium — unlock every analyst's score, rank and success rate.
Implied return = price target ÷ yesterday's close − 1: the move the stock would make if the analyst's target were hit. These are forward-looking predictions, not realized returns. Only reliable-basis calls are included; the consensus figures above are computed from the calls in this table.